Stockscreener 앱 받기
17.10
0.06%
-0.010
시장 영업 전:
17.15
0.05
+0.29%
전일 마감가:
$17.11
열려 있는:
$17.24
하루 거래량:
4.59M
Relative Volume:
0.99
시가총액:
$3.84B
수익:
$2.23B
순이익/손실:
$-248.39M
주가수익비율:
-6.3569
EPS:
-2.69
순현금흐름:
$-697.55M
1주 성능:
-9.38%
1개월 성능:
-54.52%
6개월 성능:
-85.94%
1년 성능:
-89.18%
1일 변동 폭
$16.96
$17.52
1주일 범위
$16.96
$19.43
52주 변동 폭
$16.96
$162.95
사렙타 테라퓨틱스 Stock (SRPT) Company Profile
명칭
Sarepta Therapeutics Inc
전화
617-274-4000
주소
215 FIRST STREET, CAMBRIDGE, MA
SRPT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
17.10 | 3.84B | 2.23B | -248.39M | -697.55M | -2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.20 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
525.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.09 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
551.22 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
사렙타 테라퓨틱스 Stock (SRPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-16 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-06-16 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | 다운그레이드 | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-04-11 | 개시 | Wells Fargo | Overweight |
| 2025-04-02 | 업그레이드 | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-11-27 | 재확인 | Needham | Buy |
| 2024-11-25 | 개시 | H.C. Wainwright | Sell |
| 2024-11-07 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | 개시 | Jefferies | Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-07-29 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-05-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-01-31 | 개시 | BMO Capital Markets | Outperform |
| 2023-12-13 | 재개 | Citigroup | Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-11-21 | 개시 | Wedbush | Outperform |
| 2023-10-31 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-06-23 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-04-26 | 개시 | SMBC Nikko | Outperform |
| 2023-04-04 | 개시 | Citigroup | Buy |
| 2023-03-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | 재확인 | BTIG Research | Buy |
| 2022-12-16 | 업그레이드 | UBS | Neutral → Buy |
| 2022-04-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-01-05 | 재확인 | Needham | Buy |
| 2021-12-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-05 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-09-15 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-08-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-01-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-01-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-01-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | 개시 | Berenberg | Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-20 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | 개시 | Mizuho | Buy |
| 2019-11-01 | 개시 | Guggenheim | Buy |
| 2019-08-21 | 재확인 | Needham | Buy |
| 2019-07-09 | 재확인 | Morgan Stanley | Overweight |
| 2019-07-01 | 재확인 | RBC Capital Mkts | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-11 | 재확인 | Credit Suisse | Outperform |
| 2018-10-12 | 개시 | Bernstein | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-26 | 재확인 | RBC Capital Mkts | Outperform |
| 2018-09-14 | 재개 | BofA/Merrill | Buy |
| 2018-09-06 | 개시 | Credit Suisse | Outperform |
| 2018-08-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | 재확인 | Robert W. Baird | Outperform |
| 2018-06-20 | 재확인 | Needham | Buy |
| 2018-06-19 | 재확인 | H.C. Wainwright | Buy |
모두보기
사렙타 테라퓨틱스 주식(SRPT)의 최신 뉴스
Sarepta Therapeutics’ SWOT analysis: gene therapy leader faces safety hurdles - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta - Bluefield Daily Telegraph
Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences - MarketBeat
Sarepta Therapeutics (SRPT): Mizuho Lowers Price Target to $40 | SRPT Stock News - GuruFocus
Roku upgraded, Sarepta downgraded: Wall Street’s top analyst calls - Yahoo Finance
Sarepta (SRPT) Faces Price Target Cut Amid Liver Failure Concerns | SRPT Stock News - GuruFocus
TD Cowen downgrades Sarepta Therapeutics to 'hold' - TradingView
Sarepta stock plunges 42% after second fatal liver failure case - Investing.com
Another Gene Therapy Death; Biopharma M&A Picks Up; a Vaccine Board of Vaccine Skeptics - BioSpace
Sarepta (SRPT) Downgraded to Hold with Revised Price Target | SRPT Stock News - GuruFocus
Analysts recommendations: Sarepta Therapeutics, Broadcom, Enphase Energy, Lam Research… - MarketScreener
Sarepta stock downgraded by TD Cowen on Elevidys approval concerns - Investing.com
Sarepta: TD Cowen downgrades rating, cuts PT on FDA pullback risk for Elevidys - Investing.com
Sarepta Therapeutics (SRPT) Price Target Lowered by Deutsche Ban - GuruFocus
Sarepta Therapeutics: Overcoming Challenges and Capturing Growth Opportunities Amid Elevidys Setback - TipRanks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc.SRPT - PR Newswire
Second Patient Dies Following Treatment With Sarepta’s DMD Gene Therapy Elevidys - CGTLive®
Sarepta Therapeutics price target lowered to $28 on safety concerns - Investing.com
Sarepta Therapeutics price target lowered to $28 on safety concerns By Investing.com - Investing.com UK
Sarepta Therapeutics (SRPT) PT Lowered to $28 at Evercore ISI - StreetInsider
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm | FinancialContent - FinancialContent
Sarepta Therapeutics (NasdaqGS:SRPT) SRP-9003 Gene Therapy Earns FDA Platform Technology Designation - simplywall.st
Sarepta Therapeutics (SRPT) Downgraded by Goldman Sachs to Neutral | SRPT Stock News - GuruFocus
Sarepta Therapeutics (SRPT) Downgraded by Morgan Stanley | SRPT Stock News - GuruFocus
Sarepta Therapeutics (SRPT) Target Price Slashed by Baird | SRPT Stock News - GuruFocus
From $172 to $20: Sarepta’s Spectacular Fall - Trefis
Sarepta Reports Second Death of Patient Using Its Gene Therapy - MSN
Sarepta Therapeutics’ SWOT analysis: gene therapy pioneer faces safety hurdles By Investing.com - Investing.com South Africa
Lilly adds highest Zepbound doses to DTC offering - statnews.com
Sarepta Therapeutics (SRPT) Target Price Slashed by Barclays | S - GuruFocus
Sarepta Therapeutics (SRPT) Target Price Slashed by Barclays | SRPT Stock News - GuruFocus
Pharmalittle: We're reading about a Lilly deal, a gene therapy shock for Duchenne families, and more - statnews.com
Sarepta Therapeutics’ SWOT analysis: gene therapy pioneer faces safety hurdles - Investing.com India
SRPT BREAKING NEWS: Sarepta Therapeutics, Inc. is being Investigated for Securities Fraud after Second Elevidys Death; Investors with Losses are Notified to Contact BFA Law - Business Wire
SRPT Stock: What’s Happening With Sarepta Therapeutics? - Forbes
Sarepta Therapeutics (SRPT): Analyst Lowers Price Target Amid In - GuruFocus
Sarepta (SRPT) Price Target Slashed, Uncertainty Surrounds Future | SRPT Stock News - GuruFocus
Wolfe Research Initiates Sarepta (SRPT) with Neutral Outlook Ami - GuruFocus
Wolfe Research Initiates Sarepta (SRPT) with Neutral Outlook Amid Safety Concerns | SRPT Stock News - GuruFocus
This Week’s CGT News: Investigating the Long-Term Safety of Gene Therapy for Hemophilia B - themedicinemaker.com
2nd death reported in Sarepta gene therapy trial for Duchenne muscular dystrophy - MSN
Biotech pauses trial after second patient death linked to gene therapy - The Washington Post
Sarepta Therapeutics Stock Plunges as Second Patient Dies Taking Its Drug - MSN
Sarepta (SRPT) Faces Price Target Cut Amid Gene Therapy Concerns - GuruFocus
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm - FinancialContent
Elevidys’ second liver death hits Sarepta, sends DMD ripples - BioWorld MedTech
Sarepta Market Dynamics For Elevidys Imperiled By Second Patient Death - insights.citeline.com
Sarepta shares crash as second patient dies after receiving its gene therapy - MSN
Health Care Down as Sarepta Slides -- Health Care Roundup - MarketScreener
Second patient death reported with gene therapy for muscular dystrophy - Hazleton Standard Speaker
Second Teenage Boy Dies From Liver Failure After Sarepta Gene Therapy Treatment - Bloomberg
사렙타 테라퓨틱스 (SRPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
사렙타 테라퓨틱스 주식 (SRPT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Barry Richard | Director |
May 13 '25 |
Option Exercise |
19.23 |
20,246 |
389,359 |
2,954,317 |
| Nicaise Claude | Director |
Mar 12 '25 |
Option Exercise |
25.18 |
9,746 |
245,404 |
30,303 |
| Nicaise Claude | Director |
Mar 12 '25 |
Sale |
99.64 |
2,491 |
248,203 |
27,812 |
0.78%
0.23%
자본화:
|
볼륨(24시간):